# 172 Clinical Translation and Linguistic Validation at Scale with ICON’s Brian Mallon

Understanding ICON and Its Role in Clinical Research

Introduction to Language Services in Clinical Research

• Language services, including medical translation and linguistic validation, are essential in clinical research, particularly during multinational phase three trials involving diverse linguistic backgrounds.

Overview of ICON

• ICON is one of the largest contract clinical research organizations (CROs) globally, headquartered in Dublin with over 40,000 employees and a market cap of $20 billion.

• The organization accelerates drug and device development aimed at improving patients' quality of life by providing outsourced services to various sectors including pharmaceutical and biotechnology companies.

Growth Story of ICON

• Founded in 1990 by five individuals in Dublin, ICON has grown significantly to employ over 41,000 people across 50 countries.

Brian Mallon's Role at ICON

• Brian Mallon serves as the Senior Vice President of Commercialization and Outcomes at ICON. His division includes three main groups: Real-World Solutions, Medical Device and Diagnostics, and Patient Centered Sciences.

Clinical Development Process Explained

• The clinical cycle consists of phases that a drug or medical treatment undergoes before public approval. It evaluates safety, efficacy, dosage, side effects, and risks.

Breakdown of Phases:

1. Phase One:

• Involves small groups (less than 100 healthy volunteers), focusing on safety assessment and potential side effects.

2. Phase Two:

• Administers treatment to larger patient groups with the targeted condition to further evaluate safety and effectiveness.

3. Phase Three:

• Conducted on several hundred to thousands of participants globally; compares new treatments against existing standards or placebos for comprehensive data collection.

4. Phase Four (Post-Marketing):

Understanding Phase Four Trials and Language Services in Clinical Research

Overview of Phase Four Trials

• Phase four trials, also known as marketing surveillance or post-approval studies, occur after a treatment has received regulatory approval (e.g., FDA, EMA). They monitor long-term safety and effectiveness in a larger patient population.

• These trials may explore new indications or uses for the approved treatment, ensuring ongoing evaluation beyond initial approval.

ICON's Role in Drug Development

• ICON is recognized as one of the world's leading Contract Research Organizations (CROs), providing extensive support throughout the drug development process from phase one to phase four.

• ICON does not own any drugs or devices; instead, it supports pharmaceutical companies in developing their products while managing documentation and regulatory compliance.

Language Services Integration

• ICON's language services are synergistic with its customer base, which includes pharma, biotechnology, medical device companies, and public health organizations within life sciences.

• The language services team focuses on enhancing clinical trial processes by improving data quality and participant diversity through culturally appropriate materials.

Importance of Medical Translation

• Language services encompass both patient-facing materials and complex regulatory documentation. This capability is essential for multinational studies involving diverse linguistic backgrounds.

• Key areas requiring medical translation include informed consent forms—critical for ethical research—and study protocols that ensure accurate data collection across languages.

Enhancing Patient Engagement

• Effective communication with patients is vital throughout clinical research. Translating educational materials helps facilitate understanding and adherence to study requirements.

• The role of medical translation extends beyond simple language conversion; it requires expertise in medical terminology and cultural nuances to ensure accuracy.

Structure of the Language Services Team

• The language services team at ICON operates as a distinct unit within the organization but collaborates with other divisions for broader medical expertise.

Insights on ICON's Language Services Strategy

The Role of Language Services in Clinical Research

• ICON leverages its position within the broader organization to access specialized therapeutic, medical, and scientific knowledge essential for delivering quality products to clients and patients.

• There has been a notable shift among large CROs (Contract Research Organizations) towards insourcing language services rather than relying on external language service providers (LSPs).

• Other CROs are also beginning to insource these services, indicating a trend that may continue due to various factors influencing operational strategies.

Key Factors Driving Insourcing

• Cost savings and increased efficiency are primary motivations for CROs to consider insourcing language services over outsourcing.

• Faster turnaround times for time-sensitive tasks can be achieved through internal integration of translation activities.

• Insourcing fosters seamless collaboration between language services teams and other divisions within ICON, enhancing overall project delivery.

Importance of Quality and Risk Management

• Translation errors in clinical settings carry significant risks; the cost of failure is high due to potential impacts on patient safety and regulatory compliance.

• ICON maintains a low tolerance for errors in translations, emphasizing the critical nature of content accuracy in clinical research.

• Quality assurance processes include stringent audits, ongoing training, and adherence to industry standards like ISO certifications to mitigate risks associated with translation errors.

Conclusion: Strategic Imperative for ICON

Linguistic Validation in Clinical Outcome Assessments

Importance of Linguistic Validation

• The speaker emphasizes that linguistic validation is a critical service for their organization, unlike other players who may overlook its importance.

• Linguistic validation is essential for ensuring the accuracy and cultural relevance of clinical outcome assessments (COAs), which are vital for sponsors and clients.

Understanding Clinical Outcome Assessments (COAs)

• COAs measure patient-reported outcomes such as symptoms, quality of life, and treatment satisfaction in both clinical research and healthcare settings.

• These assessments represent the "voice of the patient" and can serve as primary or secondary endpoints in drug approval submissions.

Process of Linguistic Validation

• The process ensures that COAs maintain conceptual equivalence and psychometric properties across different languages and cultures.

• A team comprising translation experts, clinicians, researchers, and subject matter experts conducts linguistic validation to ensure accuracy.

Steps Involved in Linguistic Validation

• The process begins with forward translation by qualified translators fluent in both source and target languages. This is followed by a reconciliation process to address discrepancies.

• Back translation occurs next, along with cognitive debriefing interviews with representatives from the target population to assess clarity and cultural appropriateness.

Key Considerations During the Process

• Ensuring semantic equivalence, cultural relevance, conceptual understanding, and linguistic clarity is crucial to avoid bias or distortion in data collection.

• ICON leads through Mapi Research Trust with one of the most comprehensive libraries of COAs supported by their language services team.

Impact of Regulatory Changes on Language Services

Recent Regulatory Developments

• Discussion on changes within the regulatory environment over the past two to three years highlights new EU regulations affecting clinical trials.

Effects on Language Services

• The speaker expresses hope that these changes will enhance trial efficiency within Europe while centralizing submissions through the Clinical Trials Information System (CTIS).

Efficiency in Clinical Trial Translation

Optimizing Translation Processes

• The hope for the industry is to gain efficiency by reducing unnecessary translation work, particularly for key documents in clinical trials that may not require supporting translations unless mandated by specific country regulations.

• A reduction in workload would be welcomed within the CRO sector, emphasizing the importance of delivering only necessary and value-added services to clients.

Market Comparisons and Innovations

• Compared to Europe, the U.S. market is less complicated regarding language services; however, there is a continuous effort to improve service efficiency independent of regulatory changes.

• An introduction to ICON's iTrans translation management system (TMS), which serves as a core project management tool for tracking translation projects across ICON.

Functionality of iTrans TMS

• The iTrans TMS allows clients to submit new translation requests, review past requests, approve quotes, and receive completed documents and certificates.

• It facilitates communication with consultant linguists by enabling them to accept offers from ICON staff and submit invoices while integrating with other internal systems.

Integration and Benefits of Technology

• The integration of iTrans TMS into various systems enhances its utility by placing it where users typically perform their tasks, streamlining access to language services.

• With advancements like ChatGPT influencing discussions around AI in the language industry, there's potential for these technologies to enhance business operations significantly.

Future Trends in Language Services

• AI will play an increasingly vital role in language services at ICON, improving timelines and eliminating repetitive tasks while maintaining linguistic validation's importance.

• Embracing AI trends is seen as essential for both ICON and the broader industry moving forward.

Mergers & Acquisitions Strategy

• Discussion on previous acquisitions like Mapi highlights a focus on organic growth through efficient customer service while remaining open to strategic acquisitions aligned with future industry needs.

• Continuous evaluation of potential acquisitions ensures that ICON stays ahead or keeps pace with evolving trends within the life sciences sector.

Conclusion